Contact Dormotech

ENT Diagnostics

Elevating ENT Outcomes with Objective Respiratory Data

Contact

Type II PSG for ENT: Pre-Operative Sleep Apnea Diagnostics

For the Otolaryngologist, a standard AHI score is often insufficient for surgical planning. Effective intervention—whether it involves septoplasty, UPPP, or hypoglossal nerve stimulation—requires a granular understanding of respiratory effort and sleep architecture. DormoVision X™ provides a high-fidelity, 38-channel Type II polysomnography solution that delivers in-lab precision in a home-based format. By capturing EEG-validated sleep stages alongside multi-band respiratory signals, ENT specialists can accurately phenotype patients and ensure surgical outcomes are backed by gold-standard evidence.

Key Benefits

Comprehensive Upper Airway Phenotyping: Go beyond basic airflow monitoring. DormoVision X™ utilizes dual-band respiratory effort sensors and high-resolution oximetry to provide a detailed view of inspiratory effort and paradoxical breathing. This data is critical for identifying the physiological drivers of obstruction and predicting the success of specific surgical interventions.

EEG-Validated Sleep Staging (6-Channel Suite): Identifying REM-related apnea is vital for surgical clearance. Unlike Level III tests that “estimate” sleep, our 6-channel EEG suite allows you to correlate obstructive events with specific sleep stages. This prevents the “under-diagnosis” of severe apnea that occurs only during REM, providing a complete picture of sleep fragmentation.

Nasal Patency Friendly, Wireless & Cannula-Free: Traditional nasal cannulas are often incompatible with patients suffering from severe septal deviation, nasal polyps, or valve collapse. DormoVision X™ features a wireless, mask-integrated design that eliminates the need for intranasal sensors, ensuring a comfortable and accurate study for patients with compromised nasal airways.

Clinically Validated Precision (0.97 Kappa Agreement): Trust your data as you would an in-lab study. With a 0.97 Cohen’s Kappa and 96.6% severity classification agreement compared to the Nox A1 gold standard, DormoVision X™ meets the rigorous diagnostic requirements for documenting medical necessity and securing surgical authorizations.

Features

  • One Platform, Full PSG Capability At Home or In-Lab.
  • Wireless, Remote, And FDA-Cleared.
  • 38 Total Channels For Comprehensive Sleep Data.
  • Faster Diagnoses with Greater Clinical Confidence.
  • Expand Capacity, Reduce Costs, No Added Overhead.
  • Patient-Friendly Solution for Diagnosing Complex Sleep Disorders in Children

 

Validated via NCT06224972 (N=47)

  • Nox A1 Comparison: Virtually identical mean AHI values recorded head-to-head.

  • Severity Match: Near-perfect alignment in distinguishing mild, moderate, and severe OSA cases.

  • Signal Reliability: Strong correlations across all secondary sleep parameters with minimal variance.

Keep up to date with our latest news and announcements!

Sign up with Dormotech to stay up to date on upcoming events, releases, and new research.